VISTAGEN THERAPEUTICS, INC. Increase (Decrease) in Receivables
VISTAGEN THERAPEUTICS, INC. (VTGN) reported Increase (Decrease) in Receivables of -$1.25 million for the 9-month period ending 2016-12-31, per its 10-Q filed 2017-02-13.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInReceivables · last filed 2017-02-13
- 2016-12-31: Increase (Decrease) in Receivables 9 month -$1.25M.
- 2015-12-31: Increase (Decrease) in Receivables 9 month $0.00.
| Period end | Increase (Decrease) in Receivables 9 month |
|---|---|
| 2016-12-31 | -$1.25M 10-Q · filed 2017-02-13 |
| 2015-12-31 | $0.00 10-Q · filed 2017-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B |